www.resverlogix.com

RESVERLOGIX

Suite 202
279 Midpark Way SE
Calgary AB T2X 1M2
P 403.254.9252
F 403.256.8495
info@resverlogix.com

For Immediate Release TSX Exchange Symbol: **RVX**

Resverlogix Announces a Second Proof-of-Concept Milestone

Clear dose response and ApoA-I and HDL increases confirmed in non-human primates

Calgary, AB July 25, 2007 – Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today important data from a non-human primate study on the clinical lead compound, RVX-208. Data highlights from the study in adult African green monkeys illustrate that RVX-208 elevates both ApoA-I and HDL-c in a dose-dependent manner. When RVX-208 was administered over 28-day and 42-day treatment regimens, ApoA-I levels were increased up to 52% and HDL cholesterol levels increased up to 75%. By using a range of doses we have demonstrated a clear dose-response relationship for effects on both ApoA-I and HDL. These and other data are being used to develop an optimized dosage schedule for the planned clinical trials.

Mr. Donald McCaffrey, co-founder and CEO of Resverlogix stated, "This new data affirms that we continue to build upon our world lead for novel therapies in atherosclerosis and cholesterol management - the largest global drug market currently valued at more than US $30B. RVX-208 continues to develop rapidly and is garnering interest from a variety of key stakeholders in the life sciences sector. We look forward to moving this important new class of drugs from the highly predictable African green monkey model to human clinical trials where we are expecting very positive and exciting results," Mr. McCaffrey added.

"These extraordinary results, from this confirmatory study indicate that RVX-208 has the potential of a world class drug for atherosclerosis management," stated Dr. Jan Johansson, MD, PhD, Senior Vice President Clinical at Resverlogix. "The data confirmed the potency of RVX-208 on ApoA-I and HDL-c and added new information with robust dose-response using lower doses than the last reported monkey study. The data provide additional information to better enable the execution of our proof-of-concept tests in man. The African green monkey data, by virtue of being derived from a predictive animal model for the human situation, are useful in designing of our Phase I trial - expected to commence later this fall. The data will also help in planning of our Phase II trial," added Dr. Johansson.

"By illustrating efficacy over a wide dose range we see potential for a broad range of marketed indications in vascular disorders for RVX-208," stated Kenneth Lebioda, Senior Vice President of Business Development of Resverlogix. "Having clear increasing efficacy with ascending doses provides a broad commercial opportunity for our NexVas™ PR technology. We can now envision a variety of therapeutic doses and options for several patient groups in vascular diseases in both acute and chronic settings alike. This data strongly supports our corporate strategy of maximizing the life cycle and expanding potential value for this important new drug," stated Mr. Lebioda.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas™ program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield™, a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Theresa Kennedy
VP, Corporate Communications
Resverlogix Corp.
Phone: 604-538-7072
Fax: 403-256-8495
Email: Theresa@resverlogix.com

Kenneth Lebioda
SVP, Business & Market Development
Resverlogix Corp.
Phone: 403-254-9252
Fax: 403-256-8495
Email: Ken@resverlogix.com

Website: www.resverlogix.com